Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Oral small-molecule GLP-1 receptor agonists
8 evidence topics · 4 sources
Orforglipron: FDA approval in April 2026
Orforglipron: FDA-approved indication and limitation of use
Orforglipron: administration with or without food and dosage escalation
Orforglipron: dosage modification with CYP3A4 inhibitors and inducers
Orforglipron: design and treatment discontinuation in the labeled trial of adults without diabetes
Orforglipron: equivalence of trial capsule doses to approved tablet doses
Orforglipron: weight change in adults aged 65 years and older
“In ATTAIN-1 and ATTAIN-2, 616 randomized participants were ≥65 years of age.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At Week 72, the percent change in weight from baseline among participants from ATTAIN-1 was −7.9% (95% CI: −10.0, –5.9), −11.3% (−13.4, −9.3), and −13.0% (−15.7, −10.4) with orforglipron 5.5 mg, 9 mg, and 17.2 mg, respectively, vs. −1.6% (−3.2, 0.1) with placebo (all p < 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote